Kobayashi Pharmaceutical
4967.TChemicals
Filed as KOBAYASHI PHARMACEUTICAL CO.,LTD. (2022-08–2026-08)
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥165.7bn | ¥165.6bn | ¥173.5bn | ¥166.3bn | ¥155.3bn | ¥150.5bn |
| Operating income | ¥14.9bn | ¥24.9bn | ¥25.8bn | ¥26.7bn | ¥26.1bn | — |
| Ordinary income | ¥17.0bn | ¥26.9bn | ¥27.3bn | ¥28.3bn | ¥28.0bn | ¥27.7bn |
| Net income (owners) | ¥3.7bn | ¥10.1bn | ¥20.3bn | ¥20.0bn | ¥19.7bn | ¥19.2bn |
| Total assets | ¥275.3bn | ¥265.4bn | ¥267.5bn | ¥255.8bn | ¥252.6bn | ¥238.4bn |
| Net assets / equity | ¥211.0bn | ¥213.5bn | ¥204.8bn | ¥197.9bn | ¥195.6bn | ¥182.6bn |
| Operating cash flow | ¥25.6bn | ¥11.2bn | ¥18.4bn | ¥31.9bn | ¥22.4bn | ¥24.0bn |
| EPS (basic) | ¥49.19 | ¥135.42 | ¥268.16 | ¥259.63 | ¥252.36 | ¥245.71 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2023-01-01 → 2023-12-31 | Annual | 205 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 50 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 74 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 48 figures · EDINET |
24 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Domestic Business | ¥118.1bn | ¥14.0bn |
| International Business | ¥47.0bn | ¥810m |
| Other segments | ¥683m | ¥215m |
| Adjustments & eliminations | — | −¥66m |
| Total | ¥165.1bn | ¥14.8bn |
| Total | ¥165.7bn | ¥15.0bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.